[{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Relmapirazin","moa":"CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Relmapirazin","moa":"||CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Runway Growth Capital LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Relmapirazin","moa":"CD123","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Runway Growth Capital LLC","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Runway Growth Capital LLC"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ National Cancer Institute"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-106","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-106","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Fred Hutchinson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Fred Hutchinson Cancer Center"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Funding","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-106","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Fred Hutchinson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Fred Hutchinson Cancer Center"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-106","moa":"||CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"uBriGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Agreement","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ uBriGene","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ uBriGene"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Fred Hutchinson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Fred Hutchinson Cancer Center"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Immunology","graph2":"IND Enabling","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Fred Hutchinson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mustang Bio \/ Mustang Bio","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Mustang Bio"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-107","moa":"||IL-2-gamma receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-107","moa":"||IL-2-gamma receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-107","moa":"||IL-2-gamma receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"MB-107","moa":"||IL-2-gamma receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-107","moa":"||IL-2-gamma receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Minaris Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Agreement","leadProduct":"MB-107","moa":"||IL-2-gamma receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Minaris Regenerative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Minaris Regenerative Medicine"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-107","moa":"IL-2-gamma receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-101","moa":"Interleukin 13 receptor alpha-2 (IL13RA2)","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mustang Bio \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bio \/ City of Hope"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"MB-101","moa":"||Interleukin 13 receptor alpha-2 (IL13RA2)","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"MB-101","moa":"Interleukin 13 receptor alpha-2 (IL13RA2)","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-105","moa":"Prostate stem cell antigen (PSCA)","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Prostate stem cell antigen (PSCA)","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-104","moa":"SLAM family member 7 SLAMF7 (CS1)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MB-108","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Sirion Biotech","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2020","type":"Licensing Agreement","leadProduct":"MB-207","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Mustang Bio","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Mustang Bio"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Busulfan","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-207","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-207","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"NTLA-5001","moa":"WT1","graph1":"Oncology","graph2":"Preclinical","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Mustang Bio \/ Undisclosed"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Leiden University Medical Centre","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Leiden University Medical Centre","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Leiden University Medical Centre"}]
Find Clinical Drug Pipeline Developments & Deals by Mustang Bio
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
